logo-loader
RNS
Feedback PLC

Feedback PLC - NHS Progress and Business Update

RNS Number : 0920B
Feedback PLC
20 April 2026
 

Feedback plc

 

NHS Progress and Business Update

 

Significant scale opportunities as positive discussions continue and further funding awarded

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, announces an update on the Company's continued dialogue with NHS stakeholders with a view to fulfilling productivity requirements across the NHS.

 

Previous indications were that a central NHS decision would be made in relation to a potential contract for adoption of a widescale programme for Bleepa around the end of the 2025/26 NHS financial year (31 March 2026). The Company now understands that decisions will be delayed by at least 6-9 months due to NHS internal factors. Nevertheless, discussions have continued to progress positively with central NHS stakeholders regarding at scale opportunities for Bleepa which the Board believes have the potential to be aligned to new frontline digitisation funding which is expected to become available in the 2026/27 NHS financial year.

 

Despite the delayed decision, NHSE has extended Bleepa's existing licences at Queen Victoria Hospital NHS Foundation Trust ("QVH") (annualised contract value £495k) to cover the 9-month period ending in December 2026. This ensures that the Bleepa pathway programme can continue to expand within Sussex whilst discussions continue around the potential for a larger scale rollout. Bleepa's usage at QVH continues to grow in both user numbers and use cases. The Company recently partnered with Patients Know Best to deliver a pioneering new insomnia pathway in Sussex, and we are in active discussions with QVH around additional use cases, product optimisation and additional funding in this calendar year.

 

Focus on Core Growth Opportunities

Following discussion with the Royal Berkshire NHS Foundation Trust, the Company will not be renewing its contract for photocapture with the Trust which came to the end of its 3-year term at the end of March 2026. This is part of a managed process to focus on utilising internal resources to optimise Bleepa for core pathway opportunities which the Company believes have the potential to deliver significantly larger revenues.

 

The Bleepa pathway use case is also being demonstrated for internal pathways at the Northern Care Alliance NHS Foundation Trust where the Company has agreed a further annual contract extension with the Trust, providing the opportunity to further build the business case for expansion and funding opportunities.

 

The Board remains confident that the Company continues to provide a unique value proposition that could deliver significant impact against the NHS' primary objective of waitlist reduction and elective recovery. The Company remains in active dialogue with national NHS stakeholders underpinning confidence in the mid-term opportunity for Bleepa. The Company's cash position is being carefully managed and, based on current plans, provides a runway extending to mid-2027.

 

Dr Tom Oakley, CEO of Feedback, said:

 

"Despite the delay in the NHS's decision, we remain optimistic of a positive outcome. The additional funding to extend Bleepa licences at QVH demonstrates an ongoing commitment to our solutions.

 

"Whilst we await the outcomes of central NHS decisions, we will focus on expanding the programme at QVH and other pathway opportunities, whilst selectively exploring alternative opportunities to create shareholder value."

 

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Emma Oswick, CFO

+44 (0) 20 3997 7634

IR@fbk.com

 


Panmure Liberum Limited (NOMAD and Broker)

Emma Earl/Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

 


Walbrook PR Ltd;

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Nick Rome/Marcus Ulker

07748 325 236 or 07867 984 082

 

 

About Feedback plc

 

Feedback plc is the strategic partner to unlock productivity in health and care through digital connectivity and asynchronous collaboration. With proven expertise in system integration, we enable teams to work flexibly, share information securely, and deliver care more efficiently.

 

Bleepa® is an award-winning collaboration platform that improves the quality and productivity of patient pathways enabling health and care organisations to hit targets with their existing clinical workforce. We achieve this by connecting digital infrastructure across systems, enabling asynchronous working, reducing geographic barriers and removing unnecessary appointments.

 

Bleepa supports the shift from analogue to digital and from hospital to community-based care, by uniting essential data and teams to enhance clinical decision making and enable better coordinated care.

 

The Company has a number of growth opportunities domestically and internationally across a range of public and private healthcare markets including the NHS. Our highly scalable software-as-a-service (SaaS) based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

 

https://fbk.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBKLLFQZLZBBL
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read